New pill offers hope against advanced pancreatic cancer

A new pill for advanced pancreatic cancer has been approved in the United States after a major study showed that patients taking it lived almost twice as long as those receiving chemotherapy.

The drug is called Rasonque, with the active ingredient daraxonrasib. It is intended for certain patients whose cancer has spread and who have already received treatment.

In a trial involving 500 people, patients taking the drug lived for a median of 13.2 months. Those receiving standard chemotherapy lived for 6.7 months.

That does not mean every patient will gain an extra six months. Some may respond better than others, while the drug may not work for everyone. But with pancreatic cancer, where treatment options are limited, the results are important.

The medicine works differently from chemotherapy. It targets proteins that help cancer cells grow and is taken by mouth once a day.

It is not a cure, and it comes with possible side effects, including rashes, diarrhea, nausea, mouth sores, and tiredness. Some patients may experience more serious problems and will need close medical monitoring.

For families in Cyprus affected by cancer, the news will understandably raise questions. However, approval in the United States does not mean the drug will immediately be available here. It would first need approval in Europe, followed by decisions over whether and how it could be offered through Gesy.

There is also the question of cost. In the United States, the treatment is expected to cost hundreds of thousands of dollars a year before insurance coverage.

Pancreatic cancer is particularly dangerous because it often causes few clear symptoms at first. By the time it is discovered, it may already have spread, making it much harder to treat.

The new drug has not changed that reality overnight. But it has given doctors another way to fight a cancer that has, for far too long, left patients with very few options.